Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, today announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan tablets (favipiravir) in the prevention of Covid-19.
Apnimed announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.
City of Hope, the US-based independent biomedical research and treatment centre, has commenced phase 1 clinical trial to evaluate its first SARS-CoV-2 investigational vaccine.
British drugmaker GlaxoSmithKline (GSK) has started patient dosing in a phase 3 clinical trial to assess the safety and efficacy of the respiratory syncytial viirus (RSV) vaccine candidate for maternal immunisation.
Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.
AstraZeneca announced that its AZD1222 vaccine has demonstrated a significant effect in preventing Covid-19 in an interim analysis of clinical trials in the UK and Brazil.
Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of Covid-19.
Pfizer and BioNTech have announced that their BNT162b2 Covid-19 vaccine candidate has achieved all primary efficacy endpoints in the phase 3 study.
Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.
Merck announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP) option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.